



**G Martinelli**

**Kontakt**

G Martinelli

## Publikationen (10)

Martinelli G, Zucca E, Dietrich P, Lohri A, Vorobiof H, Heizmann M, Stahel R, Stupp R, Okkinga E, Hess U, Cerny T, Utiger U, Schmitz S, Ghielmini M. Long term follow up of patients with follicular lymphoma receiving single agent rituximab at 2 different schedules in trial SAKK 35/98. *J Clin Oncol* 2010; 28:4480-4484.

Hitz F, Ghielmini M, Zimmermann D, Bertoni F, Cogliatti S, Peterson J, Simcock M, Mingrone W, von Moos R, Zucca E, Martinelli G, Swiss Group for Clinical Cancer Research (SAKK), Bern, Switzerland. A multicentre phase II trial of gemcitabine for the treatment of patients with newly diagnosed, relapsed or chemotherapy resistant mantle cell lymphoma: SAKK 36/03. *Hematological oncology* 2009; 27:154-9.

Colleoni M, Goldhirsch A, Price K, Viale G, Aebi S, Cinieri S, Peccatori F, Green M, Gelber R, Coates A, Basser R, Martinelli G, Sun Z, International Breast Cancer Study Group. The effect of endocrine responsiveness on high-risk breast cancer treated with dose-intensive chemotherapy: results of International Breast Cancer Study Group Trial 15-95 after prolonged follow-up. *Ann Oncol* 2009; 20:1344-51.

Bernhard J, Coates A, Goldhirsch A, Price K, Castiglione-Gertsch M, Gelber R, Colleoni M, Green M, Thürlimann B, Yeo W, Aebi S, Forbes J, Hürny C, Basser R, Martinelli G, Zhang J, Zahrieh D, International Breast Cancer Study Group. Quality of life and quality-adjusted survival (Q-TWiST) in patients receiving dose-intensive or standard dose chemotherapy for high-risk primary breast cancer. *BJC* 2008; 98:25-33.

Betticher D, Cerny T, Maibach R, Cina S, Cogliatti S, Kovascovics T, von Rohr A, Beck J, Aulitzky W, Kaiser U, Dyer M, Kaufmann M, Radford J, Martinelli G, Linch D. Sequential high dose chemotherapy as initial treatment for aggressive sub-types of non-Hodgkin lymphoma: results of the international randomized phase III trial (MISTRAL). *Annals of oncology : official journal of the European Society for Medical Oncology / ESMO* 2006; 17:1546-52.

Ghielmini M, Cerny T, Wernli M, Ketterer N, Lohri A, Stahel R, Martinelli G, Fey M, Cogliatti S, Léger-Falandry C, Leoncini-Francini L, Salles G, Rufibach K, Schmitz S. Single agent rituximab in patients with follicular or mantle cell lymphoma: clinical and biological factors that are predictive of response and event-free survival as well as the effect of rituximab on the immune system: a study of the Swiss Group for Clinical Cancer Research (SAKK). *Annals of oncology : official journal of the European Society for Medical Oncology / ESMO* 2005; 16:1675-82.

Crivellari D, Goldhirsch A, Sessa C, Graffeo R, Martinelli G, Bauer J, Borner M, Hess D, Thürlimann B, Nolé F, Lombardi D, Veronesi A, Pagani O, International Breast Cancer Study Group. High incidence of central nervous system involvement in patients with metastatic or locally advanced breast cancer treated with epirubicin and docetaxel. *Annals of oncology : official journal of the European Society for Medical Oncology / ESMO* 2001; 12:353-6.

Pagani O, D'Incalci M, Zucchetti M, Graffeo R, Martinelli G, Bauer J, Borner M, Hess D, Thürlimann B, Lombardi D, Crivellari D, Nolé F, Sessa C, Goldhirsch A. Epi-doxorubicin and docetaxel as first-line chemotherapy in patients with advanced breast cancer: a multicentric phase I-II study. *Annals of oncology : official journal of the European Society for Medical Oncology / ESMO* 2000; 11:985-91.

Pagani O, Riva A, Graffeo R, Zimatore M, Zampino G, Bauer J, Borner M, Hess D, Thürlimann B, Buonadonna A, Crivellari D, Martinelli G, Sessa C, Goldhirsch A. Dose-finding study of epidoxorubicin and docetaxel as first-line chemotherapy in patients with advanced breast cancer. *Annals of oncology : official journal of the European Society for Medical Oncology / ESMO* 1999; 10:539-45.

Joss R, Stahel R, Martinelli G, Cerny T, Thürlimann B, Leyvraz S, Bacchi M, Hürny C, Alberto P, Ludwig C. Quality versus quantity of life in the treatment of patients with advanced small-cell lung cancer? A randomized phase III comparison of weekly carboplatin and teniposide versus cisplatin, adriamycin, etoposide alternating with cyclophosphamide, methotrexate, vincristine and lomustine. *Swiss Group for Clinical Cancer Research (SAKK). Annals of oncology : official journal of the European Society for Medical Oncology / ESMO* 1995; 6:41-8.

## Projekte (0)

Keine Resultate gefunden.

---

Kantonsspital St.Gallen

Rorschacher Strasse 95

CH-9007 St.Gallen

T: +41 71 494 11 11

[support.forschung@kssg.ch](mailto:support.forschung@kssg.ch)